WHO: Study finds 4 drugs have little to no effect on COVID

By: |
October 16, 2020 6:49 PM

Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led.

The World Health Organisation announced Friday the long-awaited results of its six-month Solidarity Therapeutics Trial that endeavored to see if existing drugs might have an effect on the coronavirus.The World Health Organisation announced Friday the long-awaited results of its six-month Solidarity Therapeutics Trial that endeavored to see if existing drugs might have an effect on the coronavirus.

The UN health agency says the world’s largest randomised trial of COVID-19 treatments found conclusive evidence that remdesivir, a drug used to treat US President Donald Trump when he fell ill, has little or no effect on severe cases.

The World Health Organisation announced Friday the long-awaited results of its six-month Solidarity Therapeutics Trial that endeavored to see if existing drugs might have an effect on the coronavirus.

The study, which was not peer-reviewed, found that four treatments tested – remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon – had little or no effect” on whether or not patients died within about a month or whether hospitalised patients recovered.

Most of those had already been ruled out. But remdesivir, a repurposed malaria drug, has been classified as standard-of-care in the United States, and it has been approved for use against COVID-19 in the UK and EU.

Supplies of the drug have been limited, and the European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients.

Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led.

The big story is the finding that remdesivir produces no meaningful impact on survival, he said in a statement. He said the drug is now recommended in some countries but there have been significant concerns about supply, cost and access.

This is a drug that has to be given by intravenous infusion for 5 to 10 days, noting it costs about USD 2,550 per treatment course. COVID affects millions of people and their families around the world. We need scalable, affordable, and equitable treatments.”

A cocktail of treatments given to President Trump after he tested positive for the coronavirus included remdesivir.

WHO said the study, which covered more than 30 countries, looked at the effects of the treatments on overall death rates, whether or not patients need breathing machines, and how much time patients spent recovering in hospitals.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
12,277 fresh COVID-19 cases take UP’s tally to 4,68,238; death toll 6,854
2Studying Coronavirus: Scientists grow mini-lungs to observe the impact of COVID-19 on them; details
3Europe becomes second region to cross 250,000 deaths as second COVID wave hits